End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.21 CNY | -3.44% | -1.41% | -35.73% |
Apr. 25 | B-SOFT Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 15 | B-SOFT Co.,Ltd. Proposes Final Cash Dividend for the Year 2023 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 57% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The group's high margin levels account for strong profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The firm trades with high earnings multiples: 26.31 times its 2024 earnings per share.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-35.73% | 900M | - | ||
+5.85% | 32.93B | C | ||
+20.16% | 7.94B | C- | ||
+30.81% | 4.19B | B- | ||
-25.95% | 2.8B | C- | ||
-19.96% | 1.38B | B | ||
-31.87% | 1.17B | - | ||
+8.02% | 966M | C | ||
-25.74% | 839M | - | C+ | |
-15.42% | 582M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 300451 Stock
- Ratings B-SOFT Co.,Ltd.